Summary
Twenty-nine children with tumours that had failed to respond to conventional therapy have been treated with AMSA. There were 16 patients with haematological malignancies in whom treatment was initiated at 25 mg/m2 for 3 days, increasing to 150 mg/m2 for 5 days. There were one complete and four partial remissions in these patients, all of whom had received at least 500 mg AMSA/m2. Thirteen children with solid tumours were treated. They received single doses of 120 mg/m2 initially, increasing to 100 mg/m2 for 5 days. No complete or partial responses occurred, but some antitumour activity was noted in neuroblastoma and retinoblastoma. Dose-related severe bone marrow toxicity occurred, but gastrointestinal and other toxicity was mild. An additional patient with T cell lymphoma, who received AMSA prior to a successful autologous bone marrow transplant, is described.
AMSA is an active drug in childhood leukaemia. Further studies at the maximum tolerated dose are needed to assess enough patients with any single solid tumour type. In particular, the response of neuroblastoma warrants further study. Investigation of the use of AMSA either prior to bone marrow transplantation in leukaemia or in association with autologous marrow transplant in neuroblastoma and other solid tumours may be of value.
Similar content being viewed by others
References
Ahmann F, Meyskens F, Jones S, Durie B, Alberts D, Salmon S (1980) A broad phase II trial of AMSA with in vitro stem cell culture drug sensitivity correlation. Proc AACR/ASCO 21: 369
Arlin ZA, Sklaroff RB, Gee TS, Kempin SJ, Howard J, Clarkson BD, Young CW (1980) Phase I and II trials of 4-(9-acridinylamino) methanesulfon-m-aniside in patients with acute leukaemia. Cancer Res 40: 3304
Goldsmith MA, Bhandwaj S, Ohnuma T, Greenspan EM, Rolland JF (1979) Phase I study of m-AMSA in patients with solid tumours and leukaemias. Proc AACR/ASCO 20: 344
Hall SW, Benjamin RS, Legha SS, Gutterman JU, Lo Ti Li (1979) Clinical pharmacokinetics of the new antitumour agent AMSA. Proc AACR/ASCO 20: 175
Hill Bridget T, Whelan RDH (1981) Assessments of the sensitivities of cultured human neuroblastoma cells to antitumour drugs. Paediatr Res 15: 1117
Issell BF (1980) Amsacrine (AMSA). Cancer Treat Rev 7: 73
Legha SS, Bodey GP, Keating MJ, Blumenschein GR, Hortobagyi GN, Buzdar AU, McCredie K, Freireich EJ (1979) Early clinical evaluation of acridinylamino-methanesulfon-m-aniside (AMSA) in patients with advanced breast cancer and acute leukaemia. Proc AACR/ASCO 20: 416
Rivera G, Evans WE, Dahl GV, Yee GG, Pratt CB (1980) Phase I clinical and pharmacokinetic study of 4-(9-Acridinylamino)-methanesulfon-m-anisidide in children with cancer. Cancer Res 40: 4250
Slevin ML, Shannon MS, Prentice HG, Goldman Ann, Lister TA (1981) A phase I and II study of mAMSA in acute leukaemia. Cancer Chemother Pharmacol 6: 137
Tan C, Haghbin M, Rosen G, Miller DR (1979) Acridinylamino anisidide (AMSA) in children with advanced cancer. Proc AACR/ASCO 20: 154
Yang LY, Furlong NB, Drewinko B (1980) Evaluation of the lethal activity of AMSA on cultured cells. Proc AACR/ASCO 21: 286
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Goldman, A., Malpas, J.S. Phase I and II study of AMSA in childhood tumours. Cancer Chemother. Pharmacol. 9, 53–56 (1982). https://doi.org/10.1007/BF00296763
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00296763